Total number of projects: 3
As coordinator: 1
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0.5*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2011 | 4.337.425 | 2.965.749 | 1.424.800 | 1 | 1 | |
2010 | 0 | 2.999.500 | 118.000 | 1 |
Total number of partners: 1046
Partner loyalty:
Frequent Partner: (> 2 projects): 252
Rare Partner: 794
Frequent / Rare Partner Ratio: 0.32
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2011-01-01 | Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems | DETECTIVE | coordinator | 4.337.425 | 15 |
2011-01-01 | Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis | CURELUNG | participant | 2.965.749 | 11 |
2010-11-01 | Host and viral factors in acute hepatitis C | HepaCute | participant | 2.999.500 | 17 |